12,500 Shares in Cellectar Biosciences, Inc. (NASDAQ:CLRB) Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. bought a new stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 12,500 shares of the biopharmaceutical company’s stock, valued at approximately $27,000.

Several other hedge funds also recently modified their holdings of the company. Sequoia Financial Advisors LLC acquired a new stake in shares of Cellectar Biosciences during the third quarter worth $51,000. XTX Topco Ltd boosted its stake in Cellectar Biosciences by 432.4% in the 2nd quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 51,413 shares during the last quarter. AIGH Capital Management LLC grew its holdings in Cellectar Biosciences by 8.2% in the 2nd quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company’s stock valued at $7,590,000 after buying an additional 231,270 shares during the period. Vanguard Group Inc. increased its stake in shares of Cellectar Biosciences by 146.7% during the 1st quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company’s stock valued at $4,741,000 after acquiring an additional 708,191 shares during the last quarter. Finally, Rosalind Advisors Inc. lifted its holdings in shares of Cellectar Biosciences by 35.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 3,671,550 shares of the biopharmaceutical company’s stock worth $7,857,000 after acquiring an additional 965,934 shares during the period. 16.41% of the stock is owned by institutional investors and hedge funds.

Cellectar Biosciences Price Performance

Shares of CLRB stock opened at $1.58 on Friday. The company’s fifty day moving average price is $2.02 and its two-hundred day moving average price is $2.38. The firm has a market capitalization of $65.21 million, a P/E ratio of -0.92 and a beta of 1.00. Cellectar Biosciences, Inc. has a 12 month low of $1.39 and a 12 month high of $4.45.

Cellectar Biosciences (NASDAQ:CLRB) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) EPS for the quarter. On average, sell-side analysts anticipate that Cellectar Biosciences, Inc. will post -1.53 EPS for the current year.

Wall Street Analysts Forecast Growth

CLRB has been the topic of several research reports. Oppenheimer cut their target price on Cellectar Biosciences from $14.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 19th. StockNews.com upgraded Cellectar Biosciences to a “sell” rating in a report on Thursday, September 26th.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.